Background/Objective: The prognostic impact of additional cytogenetic aberrations and molecular abnormalities (such as MDS-related mutations, mutations in myeloid genes and the KRAS/NRAS mutations) in patients with NPM1- and/or FLT3-ITD-mutated AML remains elusive. Methods: This retrospective, multicentre study of real-world data aimed to investigate the impact of these mutations and cytogenetic abnormalities on the prognosis of patients with NPM1- and/or FLT3-ITD-mutated AML, treated with intensive chemotherapy. Results: In a cohort of 161 patients, the only parameters identified to affect the outcomes (EFS and OS) were the age of the patient, primary refractory disease, the presence of a NPM1 mutation and the use of allogenic stem cell transplantation (allo-SCT) within the first complete remission. More specifically, ages below the median conferred significantly improved outcomes, whereas primary refractory disease exhibited a negative correlation with the EFS and OS. Subsequent subgroup analysis, stratifying patients into three groups (Group 1: NPM1^mutated/FLT3^wt; Group 2: NPM1^mutated/FLT3^mutated; Group 3: NPM1^wt/FLT3^mutated). revealed that allo-SCT in CR1 improved the outcomes (EFS and OS) in Groups 2 and 3, but had no additional impact in Group 1. Conclusions: Age, primary refractory disease and allogenic stem cell transplantation in the first complete response were found to have a prognostic impact on outcomes, Interestingly, no significant association was detected between the poor prognostic cytogenetic abnormalities or the presence of additional mutations in myeloid genes, MDS-related genes or KRAS/NRAS genes and the outcomes in any group of patients.

Imaging flow cytometry (ImFC) represents a significant technological advancement in the field of cytometry, effectively merging the high-throughput capabilities of flow analysis with the image-based features of microscopy. In this comprehensive review article, we take a historical perspective and delve into the evolution of this methodology, presenting its past, exploring current state-of-the-art and forecasting potential future advancements. The inception of ImFC arose from the innovative combination of a flow cytometer's hydraulics with the technology of an advanced camera. This synergistic coupling facilitated the morphological analysis of cell populations at a high-throughput scale, effectively evolving the landscape of cytometry. However, the application of ImFC faced several challenges. Among the most prominent ones, is the development and implementation of software systems that can reliably and efficiently handle the robust data acquisition and analysis inherent in ImFC. The scale and complexity of the data generated by ImFC necessitates the creation of novel analytical tools that can effectively manage and interpret this data, thus allowing us to unlock the full potential of ImFC. Interestingly, artificial intelligence (AI) algorithms have begun to be implemented on ImFC, offering a promise for enhancing analytical capabilities. The adaptability and learning capacity of AI may prove to be essential in knowledge mining from high-dimensional data produced by ImFC, potentially enabling more accurate analyses. Looking forward, we project that ImFC may become an indispensable tool, not only in research laboratories but also in clinical settings. Given the unique combination of high-throughput cytometry and detailed imaging offered by ImFC, we foresee a critical role for this technology in the next generation of scientific research and diagnostics. As such, we encourage both current and future scientists to consider the integration of ImFC as an addition to their research toolkit and clinical diagnostic routine.

Herein, we report the case of a 56-year-old male patient with acute myeloid leukemia (AML) in remission who had asymptomatic myocardial ischemia on myocardial perfusion imaging and transthoracic echocardiography. Angiography did not reveal any significant coronary artery disease. Although the etiology is not entirely clear, this case suggested that myocardial perfusion imaging should be considered in patients with AML who received idarubicin to screen for possible myocardial dysfunction.

Primary central nervous system (CNS) lymphoma or systemic non-Hodgkin lymphoma that infiltrates the CNS can cause central diabetes insipidus (CDI). Polyuria and polydipsia should raise the suspicion of CDI development in patients with lymphoma that infiltrates the CNS. CDI is effectively treated with desmopressin. However, careful monitoring of the patient's serum sodium, fluid intake, urine output, and weight is necessary because patients receiving desmopressin may develop hyponatremia, so they should be alert to recognize this side effect promptly. Moreover, CDI due to lymphoma can occasionally be reversible. Therefore, the dosage of desmopressin should be adapted during or after the treatment of lymphoma.